PL368282A1 - Kompozycje dojelitowe do zapobiegania i/lub leczenia posocznicy - Google Patents

Kompozycje dojelitowe do zapobiegania i/lub leczenia posocznicy

Info

Publication number: PL368282A1
Authority: PL; Poland
Prior art keywords: sepsis; prevention; treatment; lta; lps
Prior art date: 2001-07-27

Application number

PL02368282A

Other languages

English (en)

Other versions

PL213982B1 (pl

Inventor

Robert Jahan Joseph Hageman

Gelske Speelmans

Adrianus Johannes Maria Vriesema

Original Assignee

N.V.Nutricia

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-27

Filing date

2002-07-26

Publication date

2005-03-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8180720&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL368282(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-07-26 Application filed by N.V.Nutricia filed Critical N.V.Nutricia

2005-03-21 Publication of PL368282A1 publication Critical patent/PL368282A1/pl

2013-05-31 Publication of PL213982B1 publication Critical patent/PL213982B1/pl

Links

206010040047 Sepsis Diseases 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 3
230000002265 prevention Effects 0.000 title abstract 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
210000004837 gut-associated lymphoid tissue Anatomy 0.000 abstract 2
108010004103 Chylomicrons Proteins 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
230000003247 decreasing effect Effects 0.000 abstract 1
150000003904 phospholipids Chemical class 0.000 abstract 1
239000002243 precursor Substances 0.000 abstract 1
150000003626 triacylglycerols Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/168—Steroids
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L15/00—Egg products; Preparation or treatment thereof
- A23L15/30—Addition of substances other than those covered by A23L15/20 – A23L15/25
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Polymers & Plastics (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Food Science & Technology (AREA)
Zoology (AREA)
Animal Husbandry (AREA)
Birds (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nutrition Science (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pediatric Medicine (AREA)
Biochemistry (AREA)
Oncology (AREA)
Mycology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Cosmetics (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Plant Substances (AREA)

PL368282A 2001-07-27 2002-07-26 Zastosowanie fosfolipidów, triglicerydów i cholesterolu oraz kompozycja do podawania dojelitowego PL213982B1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP01202873		2001-07-27

Publications (2)

Publication Number	Publication Date
PL368282A1 true PL368282A1 (pl)	2005-03-21
PL213982B1 PL213982B1 (pl)	2013-05-31

Family

ID=8180720

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL368282A PL213982B1 (pl)	2001-07-27	2002-07-26	Zastosowanie fosfolipidów, triglicerydów i cholesterolu oraz kompozycja do podawania dojelitowego

Country Status (12)

Country	Link
US (2)	US7758893B2 (pl)
EP (1)	EP1411951B2 (pl)
JP (1)	JP2004536136A (pl)
CN (1)	CN1561218A (pl)
AT (1)	ATE374032T1 (pl)
AU (1)	AU2002319961A1 (pl)
CA (1)	CA2455012C (pl)
DE (1)	DE60222670T3 (pl)
DK (1)	DK1411951T4 (pl)
ES (1)	ES2294147T5 (pl)
PL (1)	PL213982B1 (pl)
WO (1)	WO2003009704A2 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2006516614A (ja) *	2003-02-05	2006-07-06	エヌ．ブイ．・ヌートリシア	敗血症の予防および／または治療のための経腸組成物
KR101395370B1 (ko)	2004-01-22	2014-05-14	유니버시티 오브 마이애미	국소용 코-엔자임 큐10 제형 및 그의 사용 방법
US7273627B2 (en) *	2004-07-20	2007-09-25	Sukanya Nimmannit	Botanical compositions having hypoglycemic, hypolipidemic and antimicrobial activities for maintaining good health in normal person and diabetic patient
US20080108548A1 (en) *	2004-11-12	2008-05-08	N.V. Nutricia	Food Composition For Rapidly Attenuating Inflammatory Responses
UA89545C2 (uk) *	2005-08-29	2010-02-10	Сепсикюр Л.Л.К.	Спосіб лікування чи попередження станів, викликаних грампозитивними бактеріями
TW200833345A (en) *	2006-11-01	2008-08-16	Novacea Inc	Use of vitamin D compounds and mimics thereof to enhance delivery of therapeutics and oxygen to tumors and other tissues
MX337408B (es)	2007-03-22	2016-03-03	Berg Llc	Formulaciones topicas que tienen biodisponibilidad aumentada.
WO2009099316A1 (en) *	2008-02-08	2009-08-13	N.V. Nutricia	Use of lipid-rich nutrition for the treatment of post-operative ileus
MX2010011032A (es)	2008-04-11	2011-03-01	Cytotech Labs Llc Star	Metodos y uso de induccion de apoptosis en celulas cancerigenas.
US20110256213A1 (en) *	2008-10-15	2011-10-20	The Board Of Trustees Of The University Of Illinois	Phospholipid micellar and liposomal compositions and uses thereof
CN102481271A (zh)	2009-05-11	2012-05-30	博格生物系统有限责任公司	利用表观代谢转变剂、多维细胞内分子或环境影响剂治疗代谢障碍的方法
SG10202010355PA (en)	2010-03-12	2020-11-27	Berg Llc	Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
GB201006012D0 (en) *	2010-04-09	2010-05-26	Ayanda As	Composition
CN103025348B (zh) *	2010-05-06	2015-09-02	阿尔法科制药有限责任公司	传递类固醇到胆甾醇酯合成组织
CA2832324C (en)	2011-04-04	2022-03-15	Berg Llc	Methods of treating central nervous system tumors
WO2012138212A1 (en)	2011-04-06	2012-10-11	N.V. Nutricia	Food composition for intra-operative tube feeding
EP2720680B1 (en)	2011-06-17	2020-02-12	Berg LLC	Inhalable pharmaceutical compositions
WO2013036102A1 (en) *	2011-09-08	2013-03-14	N.V. Nutricia	Use of infant formula with cholesterol
AU2013286876B2 (en) *	2012-07-03	2017-04-20	Jay Pravda	Methods for treating, diagnosing and/or monitoring progression of oxo associated states
US9522131B2 (en)	2013-01-11	2016-12-20	Wisconsin Alumni Research Foundation	Tannin-containing gastrointestinal formulations and methods of use
NZ713868A (en)	2013-04-08	2021-12-24	Berg Llc	Treatment of cancer using coenzyme q10 combination therapies
KR102370843B1 (ko)	2013-09-04	2022-03-04	버그 엘엘씨	코엔자임 q10의 연속주입에 의한 암치료 방법
JP6166480B2 (ja) *	2013-12-11	2017-07-19	ヘルス−エバーバイオテックカンパニーリミテッド	カロテノイドの医薬組成物
SG11201607831TA (en)	2014-03-26	2016-10-28	Abbott Lab	Nutritional supplement powder
NO20150142A1 (en) *	2015-01-30	2016-08-01	Pronova Biopharma Norge As	Enteral feeding device
WO2016128235A1 (en) *	2015-02-11	2016-08-18	Nestec S.A.	Vitamin a composition
AU2016330362B2 (en) *	2015-10-02	2020-05-07	Ethicon, Inc.	Methods and systems for treating medical devices and fluids
WO2017087576A1 (en)	2015-11-16	2017-05-26	Berg Llc	Methods of treatment of temozolomide-resistant glioma using coenzyme q10
CN108697139A (zh)	2016-02-29	2018-10-23	雅培制药有限公司	营养补充粉
JP2019512229A (ja) *	2016-03-07	2019-05-16	ネイチャーズサンシャインプロダクツ、インク．	食事療法および運動での減量および心血管代謝の健康をさらに改善するための方法および組成物
AU2017274438A1 (en) *	2016-06-02	2018-12-13	Ana Pharmaceuticals, Inc.	Methods and compositions for treatment of hypercalciuria and nephrolithiasis
JP7031662B2 (ja) *	2017-03-28	2022-03-08	味の素株式会社	腸内環境改善用食品
CA3092472A1 (en) *	2018-03-02	2019-09-06	Evonik Operations Gmbh	In vitro method for detecting intestinal barrier failure in animals
GB202113028D0 (en) *	2021-09-13	2021-10-27	Ucl Business Ltd	Sterol therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5420174A (en)	1977-07-14	1979-02-15	Otsuka Pharma Co Ltd	Nutritious food ingested through alimentary canal
IL63734A (en) *	1981-09-04	1985-07-31	Yeda Res & Dev	Lipid fraction,its preparation and pharmaceutical compositions containing same
US5135922A (en) *	1984-06-15	1992-08-04	Med-Tal, Inc.	Prevention and treatment of microbial infection by phosphoglycerides
GB9007052D0 (en)	1990-03-29	1990-05-30	Skua Investments Ltd	Pharmaceutical formulations
SE9101642D0 (sv)	1991-05-30	1991-05-30	Kabi Pharmacia Ab	Phospholipids
BR9201168A (pt) *	1992-04-02	1994-04-12	Zerbini E J Fundacao	Microemulsoes usadas como velculo para carregar quimioterapicos as celulas neoplasicas
DE69331528T2 (de) *	1992-12-23	2002-10-31	Abbott Laboratories, Abbott Park	Medizinische nahrungsmittel für die ernährungsergänzung bei metabolischen erkrankungen von säuglingen/kleinkindern
DE4327063A1 (de)	1993-08-12	1995-02-16	Kirsten Dr Westesen	Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
US5585098A (en) *	1993-11-23	1996-12-17	Ovimmune, Inc.	Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants
US5585096A (en) *	1994-06-23	1996-12-17	Georgetown University	Replication-competent herpes simplex virus mediates destruction of neoplastic cells
DE4433274A1 (de)	1994-09-19	1996-03-28	Sueddeutsche Kalkstickstoff	Verfahren zur Herstellung von fett- und cholesterinreduzierten pulverförmigen Produkten auf Eibasis mit einem hohen Gehalt an Phospolipiden
JPH08311482A (ja)	1995-05-19	1996-11-26	Nippon Oil & Fats Co Ltd	コレステロール強化油脂の調製方法
US6063946A (en)	1996-01-26	2000-05-16	Eastman Chemical Company	Process for the isolation of polyunsaturated fatty acids and esters thereof from complex mixtures which contain sterols and phosphorus compounds
US6200624B1 (en) †	1996-01-26	2001-03-13	Abbott Laboratories	Enteral formula or nutritional supplement containing arachidonic and docosahexaenoic acids
CA2259179C (en)	1996-07-03	2008-09-23	University Of Pittsburgh	Emulsion formulations for hydrophilic active agents
JP3554647B2 (ja)	1997-02-25	2004-08-18	太陽化学株式会社	油脂組成物
IL140899A0 (en) †	1998-07-17	2002-02-10	Skyepharma Inc	Lipid/polymer containing pharmaceutical compositions and processes for the preparation thereof
EP1090636A1 (en)	1999-09-13	2001-04-11	Société des Produits Nestlé S.A.	High lipid diet
US6720001B2 (en) †	1999-10-18	2004-04-13	Lipocine, Inc.	Emulsion compositions for polyfunctional active ingredients

2002
- 2002-07-26 WO PCT/NL2002/000510 patent/WO2003009704A2/en not_active Ceased
- 2002-07-26 CN CNA028192036A patent/CN1561218A/zh active Pending
- 2002-07-26 DK DK02749442.6T patent/DK1411951T4/da active
- 2002-07-26 JP JP2003515106A patent/JP2004536136A/ja active Pending
- 2002-07-26 PL PL368282A patent/PL213982B1/pl unknown
- 2002-07-26 AU AU2002319961A patent/AU2002319961A1/en not_active Abandoned
- 2002-07-26 US US10/484,884 patent/US7758893B2/en not_active Expired - Fee Related
- 2002-07-26 CA CA002455012A patent/CA2455012C/en not_active Expired - Fee Related
- 2002-07-26 EP EP02749442A patent/EP1411951B2/en not_active Expired - Lifetime
- 2002-07-26 AT AT02749442T patent/ATE374032T1/de active
- 2002-07-26 DE DE60222670T patent/DE60222670T3/de not_active Expired - Lifetime
- 2002-07-26 ES ES02749442T patent/ES2294147T5/es not_active Expired - Lifetime
2010
- 2010-06-23 US US12/821,394 patent/US20100260777A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE60222670D1 (de)	2007-11-08
DK1411951T4 (da)	2010-12-20
EP1411951B1 (en)	2007-09-26
DE60222670T2 (de)	2008-07-17
AU2002319961A1 (en)	2003-02-17
EP1411951B2 (en)	2010-11-10
CA2455012C (en)	2007-10-09
ES2294147T5 (es)	2011-04-04
CA2455012A1 (en)	2003-02-06
CN1561218A (zh)	2005-01-05
DE60222670T3 (de)	2011-08-18
ES2294147T3 (es)	2008-04-01
WO2003009704A3 (en)	2003-12-04
PL213982B1 (pl)	2013-05-31
US20040191263A1 (en)	2004-09-30
JP2004536136A (ja)	2004-12-02
ATE374032T1 (de)	2007-10-15
HK1065481A1 (en)	2005-02-25
EP1411951A2 (en)	2004-04-28
US20100260777A1 (en)	2010-10-14
US7758893B2 (en)	2010-07-20
WO2003009704A2 (en)	2003-02-06
DK1411951T3 (da)	2008-01-02

Legal Events

Date	Code	Title	Description
2013-08-30	RECP	Rectifications of patent specification

Publication	Publication Date	Title
PL368282A1 (pl)	2005-03-21	Kompozycje dojelitowe do zapobiegania i/lub leczenia posocznicy
WO2006024018A3 (en)	2006-07-20	Compositions for treating nociceptive pain
GB0213612D0 (en)	2002-07-24	Organic compounds
WO2002041837A3 (en)	2003-03-06	Treatment of mucositis
PL349028A1 (en)	2002-07-01	Cancer treatment composition and method using natural plant essential oils
BR0206639A (pt)	2004-02-25	Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares
MXPA05011886A (es)	2006-02-17	Metodos y composiciones para la prevencion y tratamiento de septicemia.
MXPA03009772A (es)	2004-02-23	Metodos y composiciones para tratar lesiones orales y del esofago.
EP1688425A3 (en)	2006-08-30	Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases
SG161259A1 (en)	2010-05-27	Method for treatment of constipation-predominant irritable bowel syndrome
PT1252184E (pt)	2008-04-15	Inibidor humano c1 produzido no leite de mamíferos transgénicos
UA88463C2 (ru)	2009-10-26	Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
WO2001030333A3 (en)	2002-02-07	Tissue factor antagonists and methods of use thereof
WO2002039994A3 (en)	2003-08-21	Methods for the treatment and prevention of urinary stone disease
WO2002094189A3 (en)	2003-04-10	Compositions and methods for treating or preventing convulsions or seizures
WO2004017917A3 (en)	2004-11-11	Method for the prevention and/or treatment of atherosclerosis
DE50207740D1 (de)	2006-09-14	Verwendung von phosphatidylserin zur behandlung des aufmerksamkeits-defizit-syndroms (adhs)
MXJL05000046A (es)	2005-12-22	Mediadores de transporte reverso de colesterol para el tratamiento de hipercolesterolemia.
WO2004091436A3 (en)	2005-02-24	Methods and compositions for treating ocular disease
EP1891947A3 (en)	2008-03-05	Use of (r)-verapamil for the treatment of abnormal increases in gastrointestinal motility
WO2002064160A8 (en)	2003-01-30	Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
DE602004005821D1 (de)	2007-05-24	Enteralpräparat zur vorbeugung gegen bzw. behandlung von sepsis
ATE357241T1 (de)	2007-04-15	Verfahren zur behandlung oder prävention von chronischen wunden und komplette nahrungszusammensetzung mit glycin und/oder leucin zur verwendung darin
MX2025004758A (es)	2025-06-02	Compuestos y su uso para el tratamiento de hemoglobinopatias
WO2004110373A3 (en)	2005-04-14	Therapeutic vaccine compositions for the treatment of type 1 diabetes